类风湿关节炎患者白细胞去除术后对英夫利昔单抗的反应改善。

Improved response to infliximab after leukocytapheresis in a patent with rheumatoid arthritis.

作者信息

Azuma Teruhisa, Ishimaru Hiroyasu, Hatta Kazuhiro, Kori Yoshiaki

机构信息

Department of General Internal Medicine, Tenri Hospital, Tenri 632-0015, Japan.

出版信息

Mod Rheumatol. 2007;17(3):253-5. doi: 10.1007/s10165-007-0576-9. Epub 2007 Jun 20.

DOI:10.1007/s10165-007-0576-9

PMID:17564785

Abstract

This is the first report on effective leukocytapheresis (LCAP) in an acquired infliximab (IFM) resistant patient with rheumatoid arthritis (RA). A 44-year-old Japanese woman with RA was treated with prednisolone, cyclosporine A, and methotrexate, which failed to stabilize the disease. Infliximab was then administered and the disease activity was controlled on December 2003. However, RA became active again on June 2004 so that LCAP was administered weekly for 5 weeks. After the LCAP treatment, the ACR20% response was obtained again and IFM has regained its efficacy.

摘要

这是关于对一名获得性英夫利昔单抗（IFM）耐药的类风湿关节炎（RA）患者进行有效白细胞分离术（LCAP）的首例报告。一名44岁患RA的日本女性接受了泼尼松龙、环孢素A和甲氨蝶呤治疗，但病情未能得到控制。随后给予英夫利昔单抗，疾病活动在2003年12月得到控制。然而，RA在2004年6月再次活跃，因此每周进行5周的白细胞分离术治疗。白细胞分离术治疗后，再次获得了美国风湿病学会（ACR）20%的反应，英夫利昔单抗恢复了疗效。